Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials

By sjmartinez • October 30, 2023

Cheema HA, Shafiee A, Athar MMT, Rafiei MA, Mehmannavaz A, Jafarabady K, Shahid A, Ahmad A, Ijaz SH, Dani SS, Minhas AMK, Nashwan AJ, Fudim M, Fonarow GC. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Front Cardiovasc Med. 2023 Oct 12;10:1273781. doi: 10.3389/fcvm.2023.1273781. PMID: 37900570; PMCID: PMC10602781.

Tags: Cardiology/Epi, dapagliflozin, empagliflozin, heart failure, HFPEF, Publications, SGLT2I

Central Adiposity and Inflammation Mediate the Association Between Ultraprocessed Food Intake and Cardiovascular Disease Risk

Haidar A, Flynn S, Rikhi R, Watson KE, Wood AC, Shapiro MD. Central Adiposity and Inflammation Mediate the Association Between Ultraprocessed Food Intake and Cardiovascular[...]

Temporal and Regional Trends in Cardiovascular Mortality Associated With Diabetes Mellitus: A Nationwide Analysis From 1999 to 2020 in the United States

Ahmed S, Ahmed S, Ahmad E, Ashraf H, Akram U, Ahmad S, Uwishema O, Hassan IN, Ullah I, Ata F, Cheema AH, Alraies C, Fonarow[...]

A Polypill Strategy to Close the Heart Failure Treatment Gap

Fonarow GC, McMurray JJV. A Polypill Strategy to Close the Heart Failure Treatment Gap. JAMA Cardiol. 2026 Sep 30. doi: 10.1001/jamacardio.2026.3727. Epub ahead of print.[...]